Real-time Estimate
Cboe BZX
07:46:38 13/05/2024 pm IST
|
5-day change
|
1st Jan Change
|
0.389
USD
|
-3.47%
|
|
-11.78%
|
-11.90%
|
Fiscal Period: December |
2022
|
2023
|
2024
|
---|
Capitalization
1 |
52.07
|
19.7
|
30.39
|
Enterprise Value (EV)
1 |
52.07
|
19.7
|
30.39
|
P/E ratio
|
-1.46
x
|
-
|
-0.66
x
|
Yield
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
33.8
x
|
EV / Revenue
|
-
|
-
|
33.8
x
|
EV / EBITDA
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
12,700
|
44,500
|
75,419
|
Reference price
2 |
4.100
|
0.4427
|
0.4030
|
Announcement Date
|
30/03/23
|
16/04/24
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
---|
Net sales
1 |
-
|
-
|
0.9
|
EBITDA
|
-
|
-
|
-
|
EBIT
1 |
-
|
-14.21
|
-24.78
|
Operating Margin
|
-
|
-
|
-2,753.78%
|
Earnings before Tax (EBT)
1 |
-
|
-26.23
|
-25.68
|
Net income
1 |
-23.01
|
-26.23
|
-25.68
|
Net margin
|
-
|
-
|
-2,853.33%
|
EPS
2 |
-2.800
|
-
|
-0.6100
|
Free Cash Flow
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
Announcement Date
|
30/03/23
|
16/04/24
|
-
|
Fiscal Period: December |
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
0.1
|
0.3
|
0.5
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-4.581
|
-3.75
|
-2.936
|
-2.943
|
-5.648
|
-5.568
|
-5.993
|
-7.574
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-5,568%
|
-1,997.67%
|
-1,514.8%
|
Earnings before Tax (EBT)
1 |
-5.262
|
-3.664
|
-7.426
|
-9.88
|
-5.872
|
-5.792
|
-6.217
|
-7.798
|
Net income
1 |
-5.262
|
-3.669
|
-7.426
|
-9.875
|
-5.872
|
-5.792
|
-6.217
|
-7.798
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-5,792%
|
-2,072.33%
|
-1,559.6%
|
EPS
2 |
-0.4000
|
-0.2500
|
-0.3700
|
-
|
-0.1500
|
-0.1400
|
-0.1400
|
-0.1800
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
15/05/23
|
14/08/23
|
14/11/23
|
16/04/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
---|
Net Debt
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
Announcement Date
|
30/03/23
|
16/04/24
|
-
|
Last Close Price
0.403
USD Average target price
2
USD Spread / Average Target +396.28% Consensus |
1st Jan change
|
Capi.
|
---|
| -11.90% | 3.04Cr | | +73.51% | 1.24TCr | | -15.28% | 822.9Cr | | +4.00% | 646.37Cr | | +14.69% | 549.99Cr | | -5.84% | 532.58Cr | | +42.58% | 510.2Cr | | -18.32% | 404.61Cr | | -29.47% | 254.35Cr | | +10.80% | 199.31Cr |
Medical Equipment
|